Algeta signs technology access deal with Lumiphore
This article was originally published in Scrip
Algeta has acquired an exclusive 12-month option to license Lumiphore's Lumi4 chelator technology within the field of therapeutic radiopharmaceuticals. The Norwegian oncology-focused company hopes to evaluate the Lumi4 technology for its ability to bind the alpha-emitter thorium-227 and link it to tumour-targeting molecules, such as antibodies. Algeta said that the benefits of licensing Lumiphore's technology could include more rapid, efficient and cost-effective chelation and conjugation processes for its radionuclide-based therapeutics, and increased conjugate stability.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.